Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2014 financial results and ongoing progress with IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
“Over the past quarter, we have continued to progress our clinical development program for IPI-145. We look forward to advancing IPI-145 through monotherapy studies in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia designed to enable registration and also to initiating new studies which further our strategy of combining IPI-145 with both current standards of care and novel, targeted therapies,” stated Adelene Perkins, chair, president and chief executive officer at Infinity. “Our goal is to transform the treatment paradigm for blood cancers by helping more patients achieve deeper and more durable responses while also liberating patients from chemotherapy.”
Help employers find you! Check out all the jobs and post your resume.
